Clinical factors associated with durable response to atezolizumab in extensive-stage small-cell lung cancer: A real-world analysis in Moscow.
Evgenia Khatkova, Demid Shchetinkin, Elizaveta Lukashova, Сергей Смолин et autres
e20160 Background: Atezolizumab (A) in combination with platinum-etoposide chemotherapy represents the current standard of care for the first-line treatment of extensive-stage small-cell lung cancer (ES-SCLC). However, sustained clinical benefit is achieved only in a limited cohort of patients (pts). Identifying predictors of …
ru (code pays fourni par la source)